Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Ross, Phillip L ^a   Cheng, Iona ^b   Liu, Xin ^b   Cicek, Mine S ^c   Carroll, Peter R ^a   Casey, Graham ^d   Witte, John S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE; CARBOXYPEPTIDASE 4; CYSTEINE; GLYCINE; PROSTATE SPECIFIC ANTIGEN; THREONINE; UNCLASSIFIED DRUG; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE A4, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; AFRICAN AMERICAN; AGE; CAUCASIAN; EARLY DIAGNOSIS; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; INTRON; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AFRICAN AMERICANS; AGE FACTORS; AGED; CARBOXYPEPTIDASES; CARBOXYPEPTIDASES A; EARLY DIAGNOSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRONS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 63049106920     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-69     Document Type: Article

References (18)

1. Jemal A Siegel R Ward E Murray T Xu J Thun MJ Cancer statistics, 2007 CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43 17237035
2. Gleason DF The Veterans Administration Cooperative Research Group Histologic Grading and Clinical Staging of Prostate Cancer Urologic Pathology: The Prostate Philadelphia: Lea & Febiger Tannenbaum M 1977:171-174.
3. Partin AW Yoo J Carter HB Pearson JD Chan DW Epstein JI Walsh PC The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer [see comments] Journal of Urology 1993, 150:110-114. 7685418
4. Partin AW Kattan MW Subong EN Walsh PC Wojno KJ Oesterling JE Scardino PT Pearson JD Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] [published erratum appears in JAMA 1997 Jul 9;278(2):118] Jama 1997, 277:1445-1451. 10.1001/ jama.277.18.1445 9145716
5. Kattan MW Eastham JA Stapleton AM Wheeler TM Scardino PT A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer Journal of the National Cancer Institute 1998, 90:766-771. 10.1093/jnci/90.10.766 9605647
6. Kattan MW Eastham JA Stapleton AMF Wheeler TM Scardino PT A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer Journal of the National Cancer Institute 1998, 90:766-771. 10.1093/jnci/90.10.766 9605647
7. D'Amico A Whittington R Malkowicz S Fondurulia J Chen M Kaplan I Beard C Tomaszewski J Renshaw A Wein A Coleman C Pretreatment Nomogram for Prostate-Specific Antigen Recurrence After Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate Cancer Journal of Clinical Oncology 1999, 17:168-172. 10458230
8. Healy DG Case-control studies in the genomic era: A clinician's guide Lancet Neurol 2006, 5:701-707. 10.1016/S1474-4422(06)70524-5 16857576
9. Witte JS Goddard KA Conti DV Elston RC Lin J Suarez BK Broman KW Burmester JK Weber JL Catalona WJ Genomewide scan for prostate cancer-aggressiveness loci Am J Hum Genet 2000, 67:92-99. 1287106 10825281 10.1086/302960
10. Huang H Reed CP Zhang JS Shridhar V Wang L Smith DI Carboxypeptidase A3 (CPA3): A novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells Cancer Res 1999, 59:2981-2988. 10383164
11. Rehli M Krause SW Kreutz M Andreesen R Carboxypeptidase M is identical to the MAX.1 antigen and its expression is associated with monocyte to macrophage differentiation J Biol Chem 1995, 270:15644-15649. 10.1074/ jbc.270.26.15644 7797563
12. Kayashima T Yamasaki K Yamada T Sakai H Miwa N Ohta T Yoshiura K Matsumoto N Nakane Y Kanetake H Ishino F Niikawa N Kishino T The novel imprinted carboxypeptidase A4 gene (CPA4) in the 7q32 imprinting domain Hum Genet 2003, 112:220-226. 12552318
13. Pallares I Bonet R Garcia-Castellanos R Ventura S Aviles FX Vendrell J Gomis-Ruth FX Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin Proc Natl Acad Sci USA 2005, 102:3978-3983. 554826 15738388 10.1073/pnas.0500678102
14. D'Amico AV Whittington R Malkowicz SB Schultz D Blank K Broderick GA Tomaszewski JE Renshaw AA Kaplan I Beard CJ Wein A Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer Jama 1998, 280:969-974. 10.1001/jama.280.11.969 9749478
15. Liu X Plummer SJ Nock NL Casey G Witte JS Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: Modification by lymphotoxin alpha Am J Epidemiol 2006, 164:984-989. 10.1093/aje/kwj294 16931544
16. Samid D Hudgins WR Shack S Liu L Prasanna P Myers CE Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers Adv Exp Med Biol 1997, 400A:501-505. 9547596
17. Dashwood RH Ho E Dietary histone deacetylase inhibitors: From cells to mice to man Semin Cancer Biol 2007. 17555985
18. Johnstone RW Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer Nat Rev Drug Discov 2002, 1:287-299. 10.1038/nrd772 12120280